http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
의학 학술지 및 종합 데이터베이스 누리집 이용에서 새로운 개념과 출판윤리의 이해
배종우,함창곡 대한의사협회 2010 대한의사협회지 Vol.53 No.8
Nowadays, we have much more convenient access to every medical journal through web sites, compared to the paper-based publications of the past. Beyond simply reading, we can compose, submit, inspect, review, and store data through these web sites. Furthermore, medical journals do not operate independently, but are rather integrated through online journal databases:therefore, an era of ubiquitous access to medical information for any purpose, has arrived. Thousands of new papers are pouring out in the flood of information everyday, so that it is very important for authors to make their research outcomes known to science scholar online especially in the options or selections of his or her own purpose of study. Therefore, a thorough understanding of database usage is necessary in order to meet authors’and readers’goals. The Journal of the Korean Medical Association (JKMA) began operating an online database (www. kjma.org) in July 2010, to keep pace with international digital journal standards. Digital publication is a very encouraging improvement in meeting contemporary reader’s’needs over the previous paper-based system. The tools and content of the journal web site will both be continuously updated. Our society ought to not only catch up with other society's but further develop our online presence in innovative ways. The authors here introduce and summarize the latest trends and ethical issues in online publication needed to manage and use the online medical databases appropriately.
배종우,한원호 대한의학회 2009 Journal of Korean medical science Vol.24 No.6
We undertook a multi-hospital collective study to evaluate outcomes of neonatal respiratory distress syndrome (RDS) patients treated with pulmonary surfactant (PS) over 17 yr in Korea (Group I; 1990/91, Group II; 1996, Group III; 2002, and Group IV; 2007). There were 60 neonates in Group I (16 hospitals), 1,179 in Group II (64), 1,595 in Group III (62), and 1,921 in Group IV (57). We adopted Bomsel’s classification to evaluate initial chest radiographic findings, categorized RDS severities, and classified response types to PS therapy. Almost all cases were treated using a single dose in Groups I and II, but 19.5% received multiple-dose therapy in Group IV. In Group IV, Bomsel’s stages III and IV composed 62.9% and initial severities of mild, moderate, and severe RDS were 23.0%, 42.0%, and 35.0%. More infants showed good response in Groups II, III, and IV than in Group I (71.7%, 66.8%, and 69.2% vs. 58.3%). Complications and mortality rate were lower in Group IV than in Groups I, II, and III (mortality rate: 14.3% vs. 40.0%, 30.0%, and 18.7%). We conclude that PS therapy in neonates with RDS had a remarkable impact on improving clinical course and outcomes over 17 yr in Korea.
배종우,김채영,정성훈,최용성 대한의학회 2019 Journal of Korean medical science Vol.34 No.25
Neonatal respiratory distress syndrome (RDS) is a disease that is unique to newborn infants. It is caused by a deficiency of pulmonary surfactant (PS), which is usually ready to be activated around the perinatal period. Until RDS was more clearly understood, it was not known why premature infants died from respiratory failure, although pathology revealed hyaline membranes in the alveoli. Surprisingly, the era of PS replacement therapy began only relatively recently. The first clinical trial investigating neonatal RDS was conducted in 1980. Since then, newborn survival has improved dramatically, which has led to significant advances in the field of neonatology. The present comprehensive review addresses PS, from its discovery to the application of artificial PS in newborns with RDS. It also reviews the history of PS in Korea, including its introduction, various commercial products, present and past research, newborn registries, and health insurance issues. Finally, it describes the inception of the Korean Society of Neonatology and future directions of research and treatment.
배종우 대한의사협회 2009 대한의사협회지 Vol.52 No.2
Several advances in premature and neonatal care, such as, development in new drugs and equipments, and improvement of medical skills, have also undoubtedly contributed to the reductions in morbidity and mortality of premature infants during last several decades in Korea. This review was conducted for focusing the development of new medical drug therapy and its clinical application and outcomes for preterm. The details of the artificial pulmonary surfactant replacement therapy for respiratory distress syndrome, indomethacin for patent ductus arteriosus, inhaled nitric oxide therapy for persistent pulmonary hypertension, total parenteral nutrition, and drugs for neonatal resuscitation program were reviewed in this paper.
배종우,최선희,한만용,나영호,이영진 대한소아청소년과학회 2011 Clinical and Experimental Pediatrics (CEP) Vol.54 No.4
Purpose: The total number of times a paper is cited, also known as the impact factor (IF) of a medical journal, is widely implied in evaluating the quality of a research paper. We evaluated the citation index data as an IF of Korean J Pediatr in Korean Medical Citation Index (KoMCI)and Journal Citation Index (JCI) of Web of Science. Methods: We calculated the IF of Korean J Pediatr at KoMCI supervised by Korean Association of Medical Journal Editors. And we estimated the IF of Korean J Pediatr by the JCI of Web of Science although it was never officially reported. Results: The IF of Korean J Pediatr on KoMCI has increased from 0.100in the year 2000, to 0.205 in 2008, and 0.326 in 2009. Although the IF of Korean J Pediatr was 0.006 in 2005, 0.018 in 2006, 0.028 in 2008,0.066 in 2009, and 0.018 in 2010 according to the JCI of Web of Science, the number of citations are steadily increasing. Conclusion: Understanding and realizing the current status will be a stepping stone for further improvement. The next objective of the Korean J Pediatr is to become registered in the SCI or SCIE. Increasing the IF according to the JCI of Web of Science is crucial in order to achieve this goal.
신생아 호흡곤란 증후군에서 인공 폐 표면활성제 보충요법 제 3보고 : 지난 15년간 한국에서의 치료 결과
배종우,김영민 대한소아청소년과학회 2004 Clinical and Experimental Pediatrics (CEP) Vol.47 No.9
목 적 : 한국에서 신생아 RDS의 치료로서 인공 PS 보충요법이 도입된 것은 1991년부터로서 그간 15년의 기간이 지났다. 이 방법은 RDS 치료법으로 정착되어 RDS 예후의 개선에 크게 이바지하였다. RDS에 대한 PS 보충요법에 관한 전국적인 조사는 그 동안 2번의 보고가 있었는데, 이 보고에 계속하여 2002년 전국 62개 병원에서의 치료성적을 보고하면서 지난 2개의 보고 결과와 비교하여, 한국에서 지난 15년 동안의 치료 성적을 보고하고자한다.방 법 : 1993년 Bae 등이 보고한 것을 제 1기, 1997년 Bae 등이 보고한 것을 제 2기로 하였고, 2002년 전국 62개 병원에서 1,595례의 인공 PS 사용례들을 대상으로 제 3기로 구분하여, 이들의 임상 양상과 치료 결과, 사망률 등을 검토하여 비교 분석하였다.결 과 : 제 3기의 결과는 다음과 같다. 전체 RDS 중에서 인공 PS 보충요법을 실시한 경우는 66.2%로 1, 2기에 비해 증가하였다. 출생체중과 재태기간으로 보아 출생체중이 작을수록, 재태기간이 짧을수록 RDS의 빈도가 높고, 인공 PS 보충요법을 실시하는 비율이 높았다. 초기 흉부 방사선 소견에서 Bomsel 분류상 정도 III과 IV의 심한 군은 67.7%였다. 호흡지표 VI에서 중등도 호흡곤란은 44.8%, 중증은 29.7%이었다. 사용된 제재는 Surfacten이 35.4%, Newfectan이 64.1%이었다. 투여 횟수로 1회 여가 79.9%, 재투여는 20.1%이었다. 투여 반응은 좋은 반응이 68.4%, 재발이 16.9%, 나쁜 반응이 14.7%이었다. 생후 28일 이내 신생아 사망은 제 3기 18.7%로 제 1기 40%, 제 2기 30%에 비해 현저한 개선이 있었다. Purpose:Surfactant replacement therapy in neonates with respiratory distress syndrome(RDS) has been used in Korea since 1990. We undertook a collective study of trials from multi-hospitals to evaluate results of neonates with RDS who were treated with surfactant during the past 15 years in Korea(Period I, P-I, 1990-91; Period II, P-II, 1996; Period-III, P-III; 2002). Methods:There were 60 neonates in P-I(16 hospitals), 1,179 in P-II(64 hospitals), 1,581 in P-III(62 hospitals). Initial chest radiological findings were classified by Bomsel's criteria. The severities of RDS were categorized by ventilatory index(VI), and types of responses after surfactant therapy were classified by changes in VI, FiO2 and a/APO2 as good, relapse and poor. Results:We used Surfacten(Japan) on P-I, Surfacten and Exosurf(USA) in P-II, and Surfacten and Newfactan(Korea) in P-III. Most of the cases were treated by single dose in P-I, II, however in P-III, 79.9% of the cases were treated with a single dose and 20.1% with multiple-dose therapy. According to the initial chest radiological findings, stage III or IV were 82% in P-I, 64% in P-II, 67.7% in P-III, respectively. According to the initial severities, mild RDS were 25.5%, moderate RDS were 44.8% and severe RDS were 29.7%, respectively in P-III. The proportion of infants with initial good responses were higher in P-II, III than P-I(58.3% vs 71.7%, 68.4%). The incidence of complications and associated diseases were similar during the three periods. The mortality rate was significantly decreased in P-III than P-I, II(40.0%, 30.0% vs 18.7%), respectively. Conclusion:We concluded that surfactant treatment in neonates with RDS has had an impact on improving clinical courses and outcome. The mortality rate in RDS was significantly decreased during the last 15 years in Korea.